Newer Immunotherapies for Myeloma- A Comprehensive Overview

Speciality: Hematology

Description:

A warm welcome to all the medical professionals in this session on Newer Immunotherapies for Myeloma: A Comprehensive Overview. The treatment landscape for multiple myeloma has been fundamentally reshaped by the emergence of powerful immunotherapies that harness the patient's own immune system to fight the cancer. This comprehensive overview will delve into the latest advancements in this field, moving beyond conventional therapies to explore novel strategies that are achieving unprecedented results, particularly in patients with relapsed or refractory disease.

The latest wave of immunotherapies includes groundbreaking treatments like bispecific T-cell engagers (BiTEs) and CAR T-cell therapy. BiTEs are engineered antibodies that act like a bridge, physically connecting a patient's T-cells to the myeloma cells. This brings the immune system's killer cells into close proximity with the cancer cells, activating them to destroy the tumor. CAR T-cell therapy, on the other hand, involves collecting a patient's T-cells, genetically modifying them in a lab to specifically recognize and attack myeloma cells (usually by targeting the BCMA antigen), and then reinfusing them into the patient's body. . These therapies have demonstrated remarkable response rates in clinical trials, offering hope to patients who have exhausted all other treatment options.

Therefore, get a comprehensive understanding of these newer immunotherapies for myeloma. Listen to the webinar, absorb the shared knowledge on these transformative treatments, and follow Hidoc for more such indispensable sessions that are driving oncology forward.

See More Webinars @ Hidoc Webinars